CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
Preliminary Characterization of STEP Platform for Delivery of Genome Editing Therapy for CMT
With CMTA support of $66,000, researchers led by Jiangbing Zhou, PhD, at Yale University are...
CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update
New Phase 2a CMT trial results are in. NMD Pharma shares details.
When Early Testing Shows a Program Is Worth Continuing
Some research ideas reach a point where early testing answers an important question: Is this work worth continuing? For EverTree Bio, that moment came through early work using the CMTA Preclinical Toolbox.
CMTA Invests $100,000 in EverTree Bio to Support Cutting-Edge Therapeutic Research for CMT1A
CMTA announces a $100,000 investment in EverTree Bio to support continued development of an early-stage therapeutic program for CMT1A. The investment builds on early testing through the CMTA Preclinical Toolbox and reflects CMTA’s role in keeping strong CMT-focused research moving when it might otherwise stall.
ACT-CMT: The Largest-Ever Study of CMT Opens [Casting] Call for More Participants
The largest CMT1A study is expanding. New participants needed, including healthy volunteers. You can move this research forward.
CMT Community Helps Achieve a Major Research Milestone with NMD Pharma
What happens when the CMT community takes action and participates in CMT research? NMD Pharma answers the question.
ENCell Announces Phase 1b/2a Stem Cell Trial for CMT1A
Could stem cells change the path of CMT research? ENCell announces stem cell clinical trial for CMT1A.
What Happens When Scientists Flip the Switch on PMP22?
What happens when scientists flip a hidden switch inside nerve cells? A CMTA-funded $281,339 study is testing whether this discovery could finally bring new treatment options for people with CMT1A.
